Patent Application for Tenosynovial Giant Cell Tumor Treatment

ChangeBridge: Patent Apps - Peptides (C07K)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085124A1) detailing compositions and methods for treating tenosynovial giant cell tumor using intra-articular delivery of anti-CSF1R antibodies. The application, filed by Kirk William Johnson, focuses on sustained drug exposure within joints.

View original document View source feed page

What changed

This document is a patent application (US20260085124A1) filed with the USPTO, detailing novel methods for treating tenosynovial giant cell tumor. The application describes compositions and techniques for intra-articular delivery of anti-CSF1R antibodies, aiming for sustained therapeutic activity within joints beyond conventional short dwell times.

As this is a patent application, it does not impose immediate regulatory obligations or deadlines on regulated entities. However, it signifies potential future developments in pharmaceutical treatments for specific joint diseases. Companies involved in drug development, particularly in oncology and rheumatology, may find this application relevant for competitive intelligence and potential licensing opportunities.

Source document (simplified)

← USPTO Patent Applications

TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR

Application US20260085124A1 Kind: A1 Mar 26, 2026

Inventors

Kirk William Johnson

Abstract

The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a joint that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.